CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Early-Stop trial tests new drug for Tough-to-Treat blood cancer
Disease control TerminatedThis study aimed to compare a new immunotherapy drug, tislelizumab, against standard chemotherapy for people with Hodgkin lymphoma that had returned or stopped responding to previous treatments. The goal was to see if the new drug could help patients live longer without their can…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug injection tested in patients with Tough-to-Treat lymphoma
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017, given as an injection under the skin, for people with advanced Hodgkin and Non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goals were to find a safe dose and see how the body hand…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC